Sheheryar Kabraji, Chief of Breast Medicine at Roswell Park Comprehensive Cancer Center, shared on LinkedIn:
“In an era where higher stage HER2+ tumors seem destined for more cytotoxic therapy, we report a case of pCR in a patient with ER+ HER2+ ILC with a chemo-free regimen and discuss molecular features leading to response.”
Title: Pathologic complete response to neoadjuvant targeted therapy in locally advanced invasive lobular breast cancer
Authors: Nouman Aziz, Sukhrob Makhkamov, Mohamed Mokhtar Desouki, Prasanna Kumar, Sheheryar Kabraji.
Read the full article.
You might find this interesting:
After T-DXd: Why Switching ADC Targets May Not Be Enough
